Handbook of Disease Burdens and Quality of Life Measures pp 1135-1149 | Cite as
Economic Burden of the Components of the Metabolic Syndrome
The components of the metabolic syndrome have been extensively defined, studied, and debated. The prevalence has risen recently and affected patients use more health care resources, and face higher morbidity and mortality, resulting in an enormous economic burden. Some studies have shown health care costs to be as much as 20% higher than those accrued by patients without the risk factors. Patients with the metabolic syndrome have been shown to have greater drug expenditures, more frequent hospitalizations, and higher utilization of outpatient and physician services. When considered alone, the individual risk factor components account for a substantial economic burden to patients, health plans, and society as a whole. The diagnosis of the metabolic syndrome as a condition may encourage appropriate management and thus help prevent disease progression and reduce the considerable economic impact.
KeywordsMetabolic Syndrome Health Care Cost Economic Burden Abdominal Obesity Medical Expenditure
List of Abbreviations:
High Blood Pressure
High-Density Lipoprotein Cholesterol
International Statistical Classification of Diseases and Related Health Problems
International Diabetes Federation
Low-Density Lipoprotein Cholesterol
Medical Expenditure Panel Survey
- NCEP-ATP III
Third National Cholesterol Education Program Adult Treatment Panel
National Health and Nutrition Examination Survey
National Medical Expenditure Survey
World Health Organization
- AHA. (2005). Heart Disease and Stroke Statistics: 2005 Update. American Heart Association, Dallas, TX.Google Scholar
- American Heart Association. (2007). Metabolic Syndrome – Statistics. Retrieved on November 19, 2007, from http://www.americanheart.org/downloadable/heart/1168553793520META07.pdf.
- CDC. (2005). Preventing Heart Disease and Stroke: Addressing the Nation’s Leading Killers. Centers for Disease Control, Atlanta.Google Scholar
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001a). JAMA. 285(19): 2486–2497.Google Scholar
- Finkelstein EA, Fiebelkorn IC, Wang G. (2003). National medical spending attributable to overweight and obesity: how much, and who’s paying? Health Aff (Millwood). (Suppl Web Exclusives): W3-219–W3-226.Google Scholar
- ICD-9data.com (2008). ICD-9-CM Database. from http://www.icd9data.com/2008/Volume1/240-279/270-279/277/277.7.htm.
- IMS Health Incorporated. (2006). Leading therapy classes by global pharmaceutical sales. Retrieved October 26, 2007, from http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_80528184_80530441,00.html.
- Joslin E. (1921). JAMA. 76: 79–84.Google Scholar
- Lindsay RS, Howard BV. (2004). 4(1): 63–68.Google Scholar
- Medco. (2007). Humanomics: understand the cost of cutting edge healthcare. Drug Trend Report. http://medco.mediaroom.com/index.php?s=64& cat=5.
- Smith DG. (2007). Am J Manag Care. Suppl. 3: S68–S71.Google Scholar
- Thorpe KE, Florence CS, Howard DH, Joski P. (2005). Health Aff (Millwood). Suppl Web Exclusives: W5-317–W5-325.Google Scholar
- (2001b). The Hidden Competitive Edge. Employers Health Coalition: 1–12. http://www.ehcaccess.org/store.asp
- (Medco Health Solutions). News release: Proprietary research reveals: metabolic syndrom – the costliest condition you’ve never heard of afflicts nearly one in four Americans. Retrieved February 21, 2008. http://phx.corporate-ir.net/phoenix.zhtml?c=131268&p=irol-newsArticle print&ID=706992&highlight